Boundless Bio is a pioneering biotechnology startup that operates in the oncology sector. The company's primary focus is on developing innovative cancer treatments for patients with oncogene amplified cancers, a type of cancer that currently lacks effective treatment options. Oncogene amplified cancers are characterized by gene amplifications, which are present in nearly 25% of all cancers and more than 400,000 new cancer cases in the US each year.

The company's groundbreaking research revolves around extrachromosomal DNA (ecDNA), a key enabling mechanism in cancer cells. ecDNA is rarely found in healthy cells but is present in almost half of all solid tumor cancers. Boundless Bio is exploiting this unique vulnerability in cancer cells to develop a new wave of cancer medicines, known as ecDNA-directed therapies (ecDTx).

Boundless Bio's business model is centered on the research, development, and commercialization of these novel cancer treatments. The company aims to generate revenue through the successful development and sale of these therapies, filling a significant gap in the market for effective treatments for oncogene amplified cancers.

Boundless Bio is the only company dedicated to treating oncogene amplified cancers and is a leader in the emerging field of ecDNA. The company's team of professional drug hunters is committed to developing powerful new cancer medicines that eliminate cancer cells' ability to use ecDNA to survive.

Keywords: Boundless Bio, oncogene amplified cancers, gene amplifications, extrachromosomal DNA (ecDNA), ecDNA-directed therapies (ecDTx), cancer treatment, biotechnology, oncology, drug development, precision oncology.